ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Guideline
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Programmed Death-Ligand 1 Expression in Triple-Negative Breast Cancer: Insights from a Mexican Cohort.Cancers · 2026Article
- Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.Journal for immunotherapy of cancer · 2026Article
- Observational
- The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis.Medicina (Kaunas, Lithuania) · 2026Article
- Capturing the inflammatory landscape within kidney compartments of human diabetic kidney disease: a digital spatial profiling study.Frontiers in endocrinology · 2026Article
- Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer.Scientific reports · 2025Article
- Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review.iLIVER · 2025Review
- Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Prognostic value of circadian rhythm-associated genes in breast cancer.World journal of surgical oncology · 2025Article
- Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Digital spatial profiling for pathologists.Virchows Archiv : an international journal of pathology · 2025Article
- Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort.Breast cancer research and treatment · 2025Observational
- A Thermo-responsive collapse system for controlling heterogeneous cell localization, ratio and interaction for three-dimensional solid tumor modeling.bioRxiv : the preprint server for biology · 2024Article
- Spatial oncology: Translating contextual biology to the clinic.Cancer cell · 2024Review
- Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.Immunomedicine · 2024Article
- Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.Journal of experimental & clinical cancer research : CR · 2024Article
- Macrophage diversity in human cancers: New insight provided by single-cell resolution and spatial context.Heliyon · 2024Review
- IDO-1 impairs antitumor immunity of natural killer cells in triple-negative breast cancer via up-regulation of HLA-G.Breast cancer (Tokyo, Japan) · 2024Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
purposeProgrammed death ligand 1 [PD-(L)1]-targeted therapies have shown modest survival benefit in triple-negative breast cancer (TNBC). PD-L1 EXPERIMENTAL
designFrom a large cohort of chemotherapy-naïve TNBC, clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME (Nanostring GeoMX) were identified in subsets of PD-L1
results228 of 499 (46%) TNBC were PD-L1
conclusionsIn this early-stage TNBC cohort, nearly 50% were PD-L1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.